JP2017514809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514809A5 JP2017514809A5 JP2016563080A JP2016563080A JP2017514809A5 JP 2017514809 A5 JP2017514809 A5 JP 2017514809A5 JP 2016563080 A JP2016563080 A JP 2016563080A JP 2016563080 A JP2016563080 A JP 2016563080A JP 2017514809 A5 JP2017514809 A5 JP 2017514809A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- occurrence
- independently selected
- membered
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 157
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 111
- 229910052760 oxygen Inorganic materials 0.000 claims description 90
- 229910052757 nitrogen Inorganic materials 0.000 claims description 82
- 229910052717 sulfur Inorganic materials 0.000 claims description 78
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 63
- 125000005842 heteroatom Chemical group 0.000 claims description 63
- 239000001301 oxygen Chemical group 0.000 claims description 63
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 56
- 239000011593 sulfur Chemical group 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 34
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 29
- 125000004429 atom Chemical group 0.000 claims description 28
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 8
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- -1 cycloaliphatic Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 238000000034 method Methods 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981273P | 2014-04-18 | 2014-04-18 | |
| US61/981,273 | 2014-04-18 | ||
| JO74/2015 | 2015-04-16 | ||
| JOP20150074 | 2015-04-16 | ||
| PCT/US2015/026275 WO2015161142A1 (en) | 2014-04-18 | 2015-04-17 | Quinoxaline compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514809A JP2017514809A (ja) | 2017-06-08 |
| JP2017514809A5 true JP2017514809A5 (enExample) | 2018-05-10 |
| JP6510556B2 JP6510556B2 (ja) | 2019-05-08 |
Family
ID=54324592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563080A Expired - Fee Related JP6510556B2 (ja) | 2014-04-18 | 2015-04-17 | キノキサリン化合物及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10144742B2 (enExample) |
| EP (1) | EP3131881A4 (enExample) |
| JP (1) | JP6510556B2 (enExample) |
| CN (1) | CN106458934B (enExample) |
| BR (1) | BR112016024298A2 (enExample) |
| CA (1) | CA2946130A1 (enExample) |
| EA (1) | EA201692091A1 (enExample) |
| TW (1) | TW201625578A (enExample) |
| WO (1) | WO2015161142A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016118565A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| KR20190074292A (ko) | 2016-10-18 | 2019-06-27 | 시애틀 지네틱스, 인크. | 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달 |
| WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
| CN106883188B (zh) * | 2017-01-19 | 2020-06-30 | 上海交通大学 | 一种5-氢-1, 4-苯并二氮杂卓类化合物及其合成方法 |
| JP2020514323A (ja) * | 2017-02-06 | 2020-05-21 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物と方法 |
| JP7178360B2 (ja) | 2017-04-07 | 2022-11-25 | ケース ウエスタン リザーブ ユニバーシティ | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
| CN110799217A (zh) | 2017-04-27 | 2020-02-14 | 西雅图基因公司 | 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物 |
| WO2019152808A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
| CA3117152A1 (en) * | 2018-10-22 | 2020-04-30 | Yale University | Identification of ppm1d mutations as a novel biomarker for nampti sensitivity |
| SG11202105345TA (en) | 2018-11-21 | 2021-06-29 | Univ Case Western Reserve | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2021102370A1 (en) * | 2019-11-21 | 2021-05-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY |
| WO2022109311A1 (en) * | 2020-11-20 | 2022-05-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing nicotinamide phosphoribosyltransferase activity |
| US20230321086A1 (en) * | 2020-11-20 | 2023-10-12 | Universiy of Pittsburgh - of the Commonwealth System of Higher Education | Methods and materials for inhibiting nicotinamide phosphoribosyltransferase activity |
| EP4262792A4 (en) * | 2020-12-18 | 2025-03-19 | The Scripps Research Institute | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISEASES |
| CN114573517B (zh) * | 2022-03-10 | 2024-04-26 | 新乡医学院 | 一种喹喔啉类化合物及其制备方法与应用 |
| EP4493551A1 (en) | 2022-03-14 | 2025-01-22 | Slap Pharmaceuticals LLC | Multicyclic compounds |
| EP4568668A2 (en) * | 2022-08-11 | 2025-06-18 | MapLight Therapeutics, Inc. | Gpr6 inverse agonists |
| WO2024233563A1 (en) * | 2023-05-09 | 2024-11-14 | Amgen Inc. | 6,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators |
| WO2025117536A1 (en) * | 2023-11-29 | 2025-06-05 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Hormone receptor modulators |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| AR043059A1 (es) * | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| US7189724B2 (en) * | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| WO2005007099A2 (en) * | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| JP2007099641A (ja) * | 2005-09-30 | 2007-04-19 | Tsumura & Co | インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物 |
| CN1966500B (zh) * | 2005-11-17 | 2011-03-30 | 中国科学院上海药物研究所 | 一类喹喔啉类衍生物、制法及用途 |
| US8119656B2 (en) * | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
| CN101514192B (zh) * | 2009-04-02 | 2012-05-23 | 山东大学 | 具有逆转肿瘤细胞多药耐药活性的喹喔啉酮类衍生物及其制备方法 |
| WO2010142735A1 (en) | 2009-06-09 | 2010-12-16 | Topotarget A/S | Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase |
| NZ598294A (en) | 2009-09-03 | 2013-07-26 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| WO2011109441A1 (en) | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| EP2552444B1 (en) | 2010-04-01 | 2018-10-10 | Council of Scientific & Industrial Research | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY |
| JP5881705B2 (ja) | 2010-09-03 | 2016-03-09 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔの阻害のための新規化合物及び組成物 |
| TW201217359A (en) | 2010-09-03 | 2012-05-01 | Forma Therapeutics Inc | Novel compounds and compositions for the inhibition of NAMPT |
| SG188367A1 (en) | 2010-09-03 | 2013-04-30 | Forma Tm Llc | Novel compounds and compositions for the inhibition of nampt |
| EP2640704A1 (en) | 2010-11-15 | 2013-09-25 | Abbvie Inc. | Nampt inhibitors |
| KR20130133219A (ko) * | 2010-12-23 | 2013-12-06 | 머크 샤프 앤드 돔 코포레이션 | Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린 |
| EP2661431B1 (en) | 2011-01-05 | 2018-07-11 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| AU2012223232B2 (en) | 2011-03-02 | 2017-05-25 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
| US20120225846A1 (en) | 2011-03-02 | 2012-09-06 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US10953012B2 (en) | 2011-04-26 | 2021-03-23 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of pask |
| KR20140027366A (ko) | 2011-05-04 | 2014-03-06 | 포르마 티엠, 엘엘씨. | Nampt의 억제를 위한 신규 화합물 및 조성물 |
| AR082889A1 (es) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones para la inhibicion de nampt |
| CA2877474A1 (en) | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| JP5980340B2 (ja) | 2011-11-11 | 2016-08-31 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔ阻害剤 |
| WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| JP2015508785A (ja) | 2012-03-02 | 2015-03-23 | ジェネンテック， インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
| DE102012004054A1 (de) | 2012-03-02 | 2013-09-05 | Volkswagen Ag | Rollfalzkopf, Anlage und Verfahren zum Rollfalzen mit einem Tandemrollensatz |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| WO2013130935A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Amido-benzyl sulfoxide derivatives |
| PT2838533T (pt) * | 2012-04-16 | 2017-11-22 | Univ Texas | Composições e métodos de modulação da atividade de 15-pgdh |
| HK1208221A1 (en) | 2012-05-11 | 2016-02-26 | Abbvie Inc. | Nampt inhibitors |
| CA2873097A1 (en) | 2012-05-11 | 2013-11-14 | Todd M. Hansen | Pyridazine and pyridine derivatives as nampt inhibitors |
| WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
| WO2013170118A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Thiazolecarboxamide derivatives for use as nampt inhibitors |
| CA2873075A1 (en) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
| MX2015000101A (es) | 2012-06-27 | 2015-06-22 | Alzheimer S Inst Of America Inc | Compuestos y usos terapéuticos de los mismos. |
| EP3087051B1 (en) | 2013-12-24 | 2020-07-15 | Oncotartis Inc. | Benzamide and nicotinamide compounds and methods of using same |
-
2015
- 2015-04-17 JP JP2016563080A patent/JP6510556B2/ja not_active Expired - Fee Related
- 2015-04-17 CA CA2946130A patent/CA2946130A1/en not_active Abandoned
- 2015-04-17 EP EP15779407.4A patent/EP3131881A4/en not_active Withdrawn
- 2015-04-17 BR BR112016024298A patent/BR112016024298A2/pt not_active Application Discontinuation
- 2015-04-17 CN CN201580032478.5A patent/CN106458934B/zh not_active Expired - Fee Related
- 2015-04-17 EA EA201692091A patent/EA201692091A1/ru unknown
- 2015-04-17 US US15/304,947 patent/US10144742B2/en not_active Expired - Fee Related
- 2015-04-17 TW TW104112475A patent/TW201625578A/zh unknown
- 2015-04-17 WO PCT/US2015/026275 patent/WO2015161142A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514809A5 (enExample) | ||
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| JP2017528475A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| JP2012532136A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| JP2017511360A5 (enExample) | ||
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| JP2011529474A (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2015532295A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| EA022119B1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90 | |
| JP2011509949A5 (enExample) | ||
| JP2010510215A5 (enExample) | ||
| RU2013149174A (ru) | Новое имидазооксазиновое соединение или его соль | |
| CA2694270A1 (en) | Substituted aryloxazoles and the use thereof | |
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| JP2015522650A5 (enExample) | ||
| JP2011509301A5 (enExample) | ||
| JP2017517512A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| JP2015500884A5 (enExample) |